Companies: 10,795·Total market cap: $144.5T
enGene Holdings Inc.

enGene Holdings Inc.

ENGNNASDAQHealthcare● Active
$1.65
+$0.01(+0.61%)
Market Cap$84471712
P/E Ratio
52W High$12.25
52W Low$1.4

enGene Holdings Inc. (ENGN) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

engn · pe ratio · data through Oct 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for enGene Holdings Inc. (ENGN) measures how much investors pay for each dollar of the company's trailing earnings. ENGN's current PE ratio of N/A is calculated by dividing its stock price of $1.65 by its TTM earnings per share of -$1.82.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-10-31

Forward P/E
N/A
FY2027 est. EPS $-1.96
Based on 7 analysts
EPS (TTM)
-$1.82
TTM · diluted EPS
PEG Ratio
0.02
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · enGene Holdings Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2020 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
enGene Holdings Inc.
enGene Holdings Inc.You
ENGN
$84MN/A-$1.82
AC Immune S.A.
AC Immune S.A.
ACIU
$223MN/A-$0.70
Altimmune, Inc.
Altimmune, Inc.
ALT
$241MN/A-$1.00
Amarin Corporation plc
Amarin Corporation plc
AMRN
$294MN/A-$1.87
Annexon, Inc.
Annexon, Inc.
ANNX
$612MN/A-$1.33
Alto Neuroscience, Inc.
Alto Neuroscience, Inc.
ANRO
$640MN/A-$2.19
Cellectis S.A.
Cellectis S.A.
CLLS
$294MN/A-$0.67

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 6 of 6 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-10-31Latest
FY2025
$-2.29
2024-10-31
FY2024
$-1.24
2023-10-31
FY2023
$-4.24
2022-10-31
FY2022
$-1.55
2021-10-31
FY2021
$-1.48
2020-10-31
FY2020
$-0.95

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for enGene Holdings Inc. (ENGN) measures how much investors pay for each dollar of the company's trailing earnings. ENGN's current PE ratio of N/A is calculated by dividing its stock price of $1.65 by its TTM earnings per share of -$1.82.

PE Ratio = Stock Price ÷ EPS (TTM)
= $1.65 ÷ -$1.82 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

ENGN pe ratio · 6 questions

ENGN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.65 and TTM EPS of -$1.82. Data sourced from Financial Modeling Prep via ENGN's SEC 10-K and 10-Q filings.

ENGN PE ratioWhat is ENGN PE ratioCurrent PE ratio of ENGNENGN PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · enGene Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08